Seung Ha Son1, Yong Nam In, Jung Soo Park2,3, Yeonho You1, Jin Hong Min4,5, Insool Yoo1,5, Yong Chul Cho1, Wonjoon Jeong1, Hong Joon Ahn1, Changshin Kang1, Byung Kook Lee6. 1. Department of Emergency Medicine, Chungnam National University Hospital, 282, Munhwa-ro, Jung-gu, Daejeon, Republic of Korea. 2. Department of Emergency Medicine, Chungnam National University Hospital, 282, Munhwa-ro, Jung-gu, Daejeon, Republic of Korea. cpcr@cnu.ac.kr. 3. Department of Emergency Medicine, College of Medicine, Chungnam National University, 282, Mokdong-ro, Jung-gu, Daejeon, Republic of Korea. cpcr@cnu.ac.kr. 4. Department of Emergency Medicine, Chungnam National University Sejong Hospital, 20, Bodeum 7-ro, Sejong, Republic of Korea. 5. Department of Emergency Medicine, College of Medicine, Chungnam National University, 282, Mokdong-ro, Jung-gu, Daejeon, Republic of Korea. 6. Department of Emergency Medicine, Chonnam National University Medical School, Gwangju, 61469, Korea.
Abstract
BACKGROUND/ OBJECTIVE: Cerebrospinal fluid (CSF) and serum lactate levels were assessed to predict poor neurologic outcome 3 months after return of spontaneous circulation (ROSC). We compared arterio-CSF differences in the lactate (ACDL) levels between two neurologic outcome groups. METHODS: This retrospective observational study involved out-of-hospital cardiac arrest (OHCA) survivors who had undergone target temperature management. CSF and serum samples were obtained immediately (lactate0), and at 24 (lactate24), 48 (lactate48), and 72 (lactate72) h after ROSC, and ACDL was calculated at each time point. The primary outcome was poor 3-month neurologic outcome (cerebral performance categories 3-5). RESULTS: Of 45 patients, 27 (60.0%) showed poor neurologic outcome. At each time point, CSF lactate levels were significantly higher in the poor neurologic outcome group than in the good neurologic outcome group (6.97 vs. 3.37, 4.20 vs. 2.10, 3.50 vs. 2.00, and 2.79 vs. 2.06, respectively; all P < 0.05). CSF lactate's prognostic performance was higher than serum lactate at each time point, and lactate24 showed the highest AUC values (0.89, 95% confidence interval, 0.75-0.97). Over time, ACDL decreased from - 1.30 (- 2.70-0.77) to - 1.70 (- 3.2 to - 0.57) in the poor neurologic outcome group and increased from - 1.22 (- 2.42-0.32) to - 0.64 (- 2.31-0.15) in the good neurologic outcome group. CONCLUSIONS: At each time point, CSF lactate showed better prognostic performance than serum lactate. CSF lactate24 showed the highest prognostic performance for 3-month poor neurologic outcome. Over time, ACDL decreased in the poor neurologic outcome group and increased in the good neurologic outcome group.
BACKGROUND/ OBJECTIVE: Cerebrospinal fluid (CSF) and serum lactate levels were assessed to predict poor neurologic outcome 3 months after return of spontaneous circulation (ROSC). We compared arterio-CSF differences in the lactate (ACDL) levels between two neurologic outcome groups. METHODS: This retrospective observational study involved out-of-hospital cardiac arrest (OHCA) survivors who had undergone target temperature management. CSF and serum samples were obtained immediately (lactate0), and at 24 (lactate24), 48 (lactate48), and 72 (lactate72) h after ROSC, and ACDL was calculated at each time point. The primary outcome was poor 3-month neurologic outcome (cerebral performance categories 3-5). RESULTS: Of 45 patients, 27 (60.0%) showed poor neurologic outcome. At each time point, CSF lactate levels were significantly higher in the poor neurologic outcome group than in the good neurologic outcome group (6.97 vs. 3.37, 4.20 vs. 2.10, 3.50 vs. 2.00, and 2.79 vs. 2.06, respectively; all P < 0.05). CSF lactate's prognostic performance was higher than serum lactate at each time point, and lactate24 showed the highest AUC values (0.89, 95% confidence interval, 0.75-0.97). Over time, ACDL decreased from - 1.30 (- 2.70-0.77) to - 1.70 (- 3.2 to - 0.57) in the poor neurologic outcome group and increased from - 1.22 (- 2.42-0.32) to - 0.64 (- 2.31-0.15) in the good neurologic outcome group. CONCLUSIONS: At each time point, CSF lactate showed better prognostic performance than serum lactate. CSF lactate24 showed the highest prognostic performance for 3-month poor neurologic outcome. Over time, ACDL decreased in the poor neurologic outcome group and increased in the good neurologic outcome group.
Authors: Jerry P Nolan; Jasmeet Soar; Alain Cariou; Tobias Cronberg; Véronique R M Moulaert; Charles D Deakin; Bernd W Bottiger; Hans Friberg; Kjetil Sunde; Claudio Sandroni Journal: Resuscitation Date: 2015-10 Impact factor: 5.262
Authors: Romergryko G Geocadin; Clifton W Callaway; Ericka L Fink; Eyal Golan; David M Greer; Nerissa U Ko; Eddy Lang; Daniel J Licht; Bradley S Marino; Norma D McNair; Mary Ann Peberdy; Sarah M Perman; Daniel B Sims; Jasmeet Soar; Claudio Sandroni Journal: Circulation Date: 2019-07-11 Impact factor: 29.690
Authors: J Düring; J Dankiewicz; T Cronberg; C Hassager; J Hovdenes; J Kjaergaard; M Kuiper; N Nielsen; T Pellis; P Stammet; J Vulto; M Wanscher; M Wise; A Åneman; H Friberg Journal: Acta Anaesthesiol Scand Date: 2018-06-21 Impact factor: 2.105
Authors: Johanna Laurikkala; Markus B Skrifvars; Minna Bäcklund; Marjaana Tiainen; Stepani Bendel; Jaana Karhu; Tero Varpula; Jukka Vaahersalo; Ville Pettilä; Erika Wilkman Journal: Shock Date: 2019-02 Impact factor: 3.454
Authors: Jonathan Elmer; Cesar Torres; Tom P Aufderheide; Michael A Austin; Clifton W Callaway; Eyal Golan; Heather Herren; Jamie Jasti; Peter J Kudenchuk; Damon C Scales; Dion Stub; Derek K Richardson; Dana M Zive Journal: Resuscitation Date: 2016-02-03 Impact factor: 5.262